Skip to main content
. 2016 Nov 24;2016(11):CD004028. doi: 10.1002/14651858.CD004028.pub4

Wang 2005a.

Methods Allocation: randomised ‐ no further description
Blinding: open label
Duration: 4 weeks
Design: not reported
Country: China
Participants Diagnosis: CCMN‐3 schizophrenia, with aggressive behaviours according to scores of MOAS > = 4
n = 60.
Sex: 35 M, 25 F
Age: total range 18‐56 years, mean 32.2 ± 7.3 years
History: mean duration of illness
Settings: inpatients
Interventions 1. Antipychotics + magnesium valproate: magnesium valproate starting dose 400 mg/d, increased to 800‐1200 mg/d after 7 days; antipsychotic drugs same as before study entry; n = 30
 2. Antipychotics + placebo: antipsychotic drugs same as before study; n = 30
Outcomes Clinical response: mental state (BPRS total) negative symptoms (BPRS subscale), aggression/agitation (MOAS, BPRS subscale), depression (BPRS subscale)
Adverse events: at least one adverse event, various events
Unable to use:
Leaving the study early: acceptability/tolerability of treatment (no information provided)
Adverse events: TESS score (not reported)
Notes No information about blinding provided, assume open‐label
Valproate group & monotherapy group no significant differences in demographic data
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk "randomly divided" (p 10)
Allocation concealment (selection bias) Unclear risk Not indicated
Blinding of participants and personnel (performance bias) 
 Objective outcomes Low risk We don't think blinding causes significant bias in objective outcome.
 No information provided about blinding provided, assume open‐label.
Blinding of participants and personnel (performance bias) 
 Subjective outcomes High risk No information provided about blinding provided, assume open‐label
Blinding of outcome assessment (detection bias) 
 Objective outcomes Low risk We don't think blinding causes significant bias in objective outcome.
Blinding of outcome assessment (detection bias) 
 Subjective outcomes High risk No information provided about blinding provided, assume open‐label
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk Not stated
Selective reporting (reporting bias) High risk TESS score measured but not reported
Other bias Low risk No other bias